Opinions

David Burrows Genzyme General Division GENZ-Q TOP PICK Jan 12, 2005

Has grown very well over the last 3 years against an industry that's had a difficult time. Risk level is relatively low. A better way to develop new drugs as opposed to the old line drug companies.

David Burrows

Owned

Unlock Rating

$59.910

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

PAST TOP PICK

(Top Pick Jan 12/05. Down 6%.) The pharmaceutical group has been out of favor. Has some good revenue growth.

PAST TOP PICK

(A Top Pick Jan 12/05. Down 1%.) The bio-techs are about the best performing group over the last little while. Diversified product line. Have a great revenue line. Still likes.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

David Burrows Genzyme General Division GENZ-Q TOP PICK Jan 12, 2005

You might be interested:

Genzyme General Division(GENZ-Q)

Genzyme General Division(GENZ-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Rebecca Teltscher

Andrey Omelchak

The Panic-Proof Portfolio (Stockchase Research)

The Monthly Gems by Allan Tong

Andrew Moffs